^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    Chr t(11;14)

    21d
    CEACAM1 expression by immunohistochemistry in B-cell lymphomas and plasma cell myeloma. (PubMed, Am J Clin Pathol)
    CEACAM1 is frequently expressed in MCL and in subsets of other mature B-cell neoplasms and MM. These findings support further investigation of CEACAM1 as a biologically relevant marker and potential therapeutic target in selected lymphoid malignancies.
    Retrospective data • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CEACAM5 (CEA Cell Adhesion Molecule 5) • TNFRSF14 (TNF Receptor Superfamily Member 14) • CEACAM1 (CEA Cell Adhesion Molecule 1)
    |
    Chr t(11;14)
    25d
    JKART-1: Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, Kite, A Gilead Company | Trial primary completion date: Nov 2025 --> Jul 2027
    Trial primary completion date
    |
    CCND1 (Cyclin D1)
    |
    Chr t(11;14)
    |
    cyclophosphamide • fludarabine IV • Tecartus (brexucabtagene autoleucel)
    27d
    Real Egyptian Single-Center Experience in Mantle Cell Lymphoma Diagnosis and Management. (PubMed, Indian J Hematol Blood Transfus)
    Patients received treatment according to the institutional protocols in the form of RCHOP [rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone] and RDHAP [rituximab, dexamethasone, high dose cytarabine and cisplatin] as induction therapy and ICE [ifosfamide, carboplatin, etoposide], ESHAP [etoposide, methylprednisolone, high dose cytarabine and cisplatin], gemcitabine-based protocols, and others as second line therapies. To overcome the limitations in our study, larger cohorts are needed to be studied with the evaluation of the novel therapies when feasible. Enhancing financial support is crucial to improve MCL patients' care in our country.
    Journal
    |
    CCND1 (Cyclin D1) • SOX11 (SRY-Box Transcription Factor 11)
    |
    Chr t(11;14)
    |
    cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine • prednisone • dexamethasone
    28d
    CARAMEL: Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=48, Active, not recruiting, University College, London | Recruiting --> Active, not recruiting | Trial completion date: Dec 2028 --> Jun 2028 | Trial primary completion date: Nov 2026 --> Jun 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    CCND1 (Cyclin D1)
    |
    Chr t(11;14)
    |
    Rituxan (rituximab) • Calquence (acalabrutinib)
    1m
    Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis (clinicaltrials.gov)
    P1/2, N=53, Recruiting, Columbia University | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Sep 2026 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Ninlaro (ixazomib) • pomalidomide • bendamustine • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Hemady (dexamethasone tablets)
    1m
    Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL (clinicaltrials.gov)
    P3, N=466, Recruiting, Alliance for Clinical Trials in Oncology | Not yet recruiting --> Recruiting | Initiation date: Jan 2026 --> Apr 2026
    Enrollment open • Trial initiation date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14)
    |
    clonoSEQ®
    |
    Brukinsa (zanubrutinib) • Beqalzi (sonrotoclax)
    1m
    Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Ninlaro (ixazomib) • Hemady (dexamethasone tablets)
    1m
    A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL) (clinicaltrials.gov)
    P1/2, N=106, Completed, Beijing InnoCare Pharma Tech Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    CCND1 (Cyclin D1)
    |
    Chr t(11;14)
    |
    Inokai (orelabrutinib)
    2ms
    Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA (clinicaltrials.gov)
    P1, N=9, Recruiting, Chinese PLA General Hospital
    New P1 trial • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD19 positive • Chr t(11;14) • CD20 negative
    2ms
    A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) (clinicaltrials.gov)
    P1/2, N=199, Recruiting, AbbVie | N=130 --> 199
    Enrollment change • Adverse events
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Chr t(11;14)
    |
    Darzalex (daratumumab) • dexamethasone • pomalidomide • surzetoclax (ABBV-453)
    2ms
    Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P2, N=20, Recruiting, National Cancer Institute (NCI) | Initiation date: Sep 2026 --> May 2026
    Trial initiation date
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • CCND1 (Cyclin D1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14)
    |
    Gomekli (mirdametinib)
    2ms
    TrAVeRse: A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=108, Active, not recruiting, AstraZeneca | Trial primary completion date: Jul 2028 --> Oct 2028 | Trial completion date: Jul 2028 --> Oct 2028
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule)
    |
    Chr t(11;14)
    |
    clonoSEQ®
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Calquence (acalabrutinib)